How to buy GW Pharmaceuticals stock (GWPH)

GW Pharmaceuticals is a drug manufacturers - general business based in the US. GW Pharmaceuticals shares (GWPH) are listed on the NASDAQ and all prices are listed in US Dollars. GW Pharmaceuticals employs 1,161 staff and has a trailing 12-month revenue of around $559 million.

Our top picks for where to buy GW Pharmaceuticals stock

Buy GW Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

GW Pharmaceuticals stock price (NASDAQ: GWPH)

Use our graph to track the performance of GWPH stocks over time.

GW Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-07-04.

52-week range	$0.00 - $0.00
50-day moving average more info button	$218.22
200-day moving average more info button	$167.56
Wall St. target price	$201.13
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$1.07

Is it a good time to buy GW Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is GW Pharmaceuticals stock undervalued or overvalued?

Valuing GW Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GW Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

GW Pharmaceuticals's PEG ratio

GW Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.37. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GW Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

GW Pharmaceuticals financials

Revenue TTM	$559 million
Gross profit TTM	$489.7 million
Return on assets TTM	-4.58%
Return on equity TTM	-9.62%
Profit margin	-12.49%
Book value	$23.35
Market Capitalization more info button	$6.8 billion

TTM: trailing 12 months

GW Pharmaceuticals share dividends

We're not expecting GW Pharmaceuticals to pay a dividend over the next 12 months.

GW Pharmaceuticals share price volatility

Over the last 12 months, GW Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GW Pharmaceuticals's is 1.6492. This would suggest that GW Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

GW Pharmaceuticals overview

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. .

Frequently asked questions

null
What percentage of GW Pharmaceuticals is owned by insiders or institutions?
Currently 0.196% of GW Pharmaceuticals shares are held by insiders and 80.351% by institutions. How many people work for GW Pharmaceuticals?
Latest data suggests 1,161 work at GW Pharmaceuticals. When does the fiscal year end for GW Pharmaceuticals?
GW Pharmaceuticals's fiscal year ends in December. Where is GW Pharmaceuticals based?
GW Pharmaceuticals's address is: Sovereign House, Cambridge, United Kingdom, CB24 9BZ What is GW Pharmaceuticals's ISIN number?
GW Pharmaceuticals's international securities identification number is: US36197T1034 What is GW Pharmaceuticals's CUSIP number?
GW Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 36197T103